Pharmaceutical company launched to explore up-to-date therapeutics

Led by Leaps by Bayer and Morningside Ventures, Vesigen Therapeutics, a Pharmaceutical company, was recently launched with investment of $ 28.5 million.

Vesigen aims to overcome the hurdle of targeted intracellular drug delivery of next-generation therapeutics, such as CRISPR-cas9, RNA molecules and other therapeutic proteins, by using a proprietary delivery technology -- ARRDC1-mediated microvesicles (ARMMs).

According to the company, the capital will be used to build out the ARMMs platform as well as to advance numerous therapeutic agents into preclinical and clinical development.